Conclusions
MDD, depression
A future definitive trial exploring the use of subcutaneous infusion of ketamine for MDD in the palliative care setting may be feasible but challenged by barriers primarily related to the clinicians’ challenges in screening, assessing and managing depression in the context of participants’ rapidly deteriorating medical conditions. Individual dose-titration of subcutaneous infusions of ultra-low ketamine dosages starting from 0.1mg/kg over two hours can be well-tolerated and produce transient antidepressant activities over hours to days.